Altimmune, Inc. (NASDAQ:ALT) Q4 2025 Earnings Call Transcript March 5, 2026 Altimmune, Inc. misses on earnings expectations. Reported EPS is $-0.27191 EPS, expectations were $-0.25. Operator: Good ...

More than half of Ozempic users prescribed the drug for obesity alone are stopping or reducing their doses within a year, ...

Novo beat Q4 consensus on revenue and adjusted EPS, driven by 31% obesity-care growth, yet shares fell nearly 40% after a ...

Novo Nordisk A/S remains a Buy despite CagriSema setback; Eli Lilly and Company remains a Hold on valuation. Click for this ...

Jakob Roze, CSCS, is a health writer and high-end personal trainer. He is the founder and CEO of RozeFit, a high-end concierge personal training practice and online blog. The downward dogs and cat-cow ...